Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator- activated receptor γ-dependent mechanism

Molecular Pharmacology

Volumn 81, Issue 2, 2012, Pages 228-238

  Uray, Iván P ^a,b   Rodenberg, Jennifer M ^b   Bissonnette, Reid P ^c   Brown, Powel H ^a,b   Mancini, Michael A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; FAT DROPLET; LGD 100268; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST EPITHELIUM; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; CONTENT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; LOW DRUG DOSE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INDUCTION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CHEMOPREVENTION; EPITHELIAL CELLS; HUMANS; LIPID METABOLISM; LIPIDS; PPAR GAMMA; TETRAHYDRONAPHTHALENES;

EID: 84856073593     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.072967     Document Type: Article

References (42)

1. Abba MC, Hu Y, Levy CC, Gaddis S, Kittrell FS, Zhang Y, Hill J, Bissonnette RP, Medina D, Brown PH, et al. (2008) Transcriptomic signature of bexarotene (rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models. BMC Med Genomics 1:40.
2. Agarwal VR, Bischoff ED, Hermann T, and Lamph WW (2000) Induction of adipocyte- specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res 60:6033-6038.
3. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, and Whittaker S (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261-266. (Pubitemid 44050557)
4. Bischoff ED, Heyman RA, and Lamph WW (1999) Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91:2118.
5. Blumenschein GR Jr, Khuri FR, von Pawel J, Gatzemeier U, Miller WH Jr, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, et al. (2008) Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26:1879-1885.
6. Brasaemle DL, Barber T, Wolins NE, Serrero G, Blanchette-Mackie EJ, and Londos C (1997) Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res 38:2249-2263. (Pubitemid 27495384)
7. Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, and Howe LR (2008) Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila) 1:208-214.
8. Cesario RM, Stone J, Yen WC, Bissonnette RP, and Lamph WW (2006) Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett 240:225-233. (Pubitemid 44093823)
9. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
10. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, and Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300. (Pubitemid 36126189)
11. de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, et al. (2009) Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology 150:2368-2375.
12. Dragnev KH, Petty WJ, Ma Y, Rigas JR, and Dmitrovsky E (2005) Nonclassical retinoids and lung carcinogenesis. Clin Lung Cancer 6:237-244. (Pubitemid 40309334)
13. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, and Heyman RA (1996) Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 56:5566-5570. (Pubitemid 26422151)
14. Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S, Wei CL, Ruan Y, et al. (2009) De-novo identification of PPARgamma/ RXR binding sites and direct targets during adipogenesis. PLoS One 4:e4907.
15. Hartig SM, He B, Long W, Buehrer BM, and Mancini MA (2011) Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. J Cell Biol 192:55-67.
16. Imamura M, Inoguchi T, Ikuyama S, Taniguchi S, Kobayashi K, Nakashima N, and Nawata H (2002) ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab 283:E775-E783.
17. Kahn BB and McGraw TE (2010) Rosiglitazone, PPARγ, and type 2 diabetes. N Engl J Med 363:2667-2669.
18. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, et al. (2001) Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 19:2626-2637. (Pubitemid 32441367)
19. Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, et al. (2006) Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 66:12009-12018. (Pubitemid 46094215)
20. Kotokorpi P, Venteclef N, Ellis E, Gustafsson JA, and Mode A (2010) The human ADFP gene is a direct liver-X-receptor (LXR) target gene and differentially regulated by synthetic LXR ligands. Mol Pharmacol 77:79-86.
21. Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, and Conklin DS (2009) Peroxisome proliferator-activated receptor-gamma protects ERBB2-positive breast cancer cells from palmitate toxicity. Breast Cancer Res 11:R16.
22. Laska EM, Meisner M, and Siegel C (1994) Simple designs and model-free tests for synergy. Biometrics 50:834-841. (Pubitemid 24320830)
23. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, and Brown PH (2007) The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res 13:6224-6231. (Pubitemid 350075084)
24. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, et al. (2006) The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptornegative model of breast cancer. Clin Cancer Res 12:5902-5909. (Pubitemid 44629624)
25. McDonough PM, Agustin RM, Ingermanson RS, Loy PA, Buehrer BM, Nicoll JB, Prigozhina NL, Mikic I, and Price JH (2009) Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high- throughput microscopy and automated image analysis. Assay Drug Dev Technol 7:440-460.
26. Mehta RG, Williamson E, Patel MK, and Koeffler HP (2000) A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92:418-423. (Pubitemid 30154824)
27. Michalik L, Desvergne B, and Wahli W (2004) Peroxisome-proliferator- activated receptors and cancers: complex stories. Nat Rev Cancer 4:61-70. (Pubitemid 38082154)
28. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, et al. (1997) Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15:790-795. (Pubitemid 27074250)
29. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, Gill GM, Ulm EH, Geiser R, Jaunakais D, et al. (1999) A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 5:1658-1664. (Pubitemid 29334442)
30. Rosen ED and Spiegelman BM (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734.
31. Russell TD, Palmer CA, Orlicky DJ, Fischer A, Rudolph MC, Neville MC, and McManaman JL (2007) Cytoplasmic lipid droplet accumulation in developing mammary epithelial cells: roles of adipophilin and lipid metabolism. J Lipid Res 48:1463-1475. (Pubitemid 47312009)
32. Schernthaner G and Chilton RJ (2010) Cardiovascular risk and thiazolidinediones: what do meta-analyses really tell us? Diabetes Obes Metab 12:1023-1035.
33. Sporn MB (1980) Combination chemoprevention of cancer. Nature 287:107-108.
34. Sporn MB, Suh N, and Mangelsdorf DJ (2001) Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 7:395-400. (Pubitemid 32823988)
35. Uray IP and Brown PH (2006) Prevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs 15:1583-1600. (Pubitemid 44848981)
36. Uray IP and Brown PH (2011) Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res 188:147-162.
37. Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, and Brown PH (2009) Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem 284:345-353.
38. Wu K, DuPré E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, and Brown PH (2006) Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat 96:147-157.
39. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, and Brown PH (2002) Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11:467-474. (Pubitemid 34517942)
40. Wu W, Celestino J, Milam MR, Schmeler KM, Broaddus RR, Ellenson LH, and Lu KH (2008) Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int J Gynecol Cancer 18:329-338. (Pubitemid 351365203)
41. Yen WC, Prudente RY, and Lamph WW (2004) Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma. Breast Cancer Res Treat 88:141-148. (Pubitemid 39575571)
42. Zhang JH, Chung TD, and Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. (Pubitemid 29278954)